When should valacyclovir be preferred over acyclovir for herpes simplex virus and varicella‑zoster virus infections, and how do their dosing regimens differ?

Valacyclovir vs Acyclovir: When to Prefer Each Agent

Valacyclovir should be preferred over acyclovir for most HSV and VZV infections in adults and adolescents due to superior pharmacokinetics, less frequent dosing (improving adherence), and demonstrated superiority in reducing herpes zoster-associated pain. 1

Key Pharmacologic Advantage

Valacyclovir is the L-valyl ester prodrug of acyclovir with 3-5 fold higher oral bioavailability compared to acyclovir 2, 3. This allows:

• Less frequent daily dosing
• Improved patient compliance
• Equivalent or superior clinical outcomes

Clinical Situations Where Valacyclovir is Preferred

Herpes Zoster (Shingles)

Valacyclovir demonstrates clear superiority over acyclovir for herpes zoster in patients ≥50 years:

• Significantly accelerates resolution of zoster-associated pain (median 38-44 days vs 51 days with acyclovir, p=0.001-0.03) 2
• Reduces postherpetic neuralgia duration and prevalence (19.3% vs 25.7% with pain at 6 months) 2
• Meta-analysis shows 36% risk reduction in pain at 21-30 days (NNT=3) 4

Dosing:

• Valacyclovir: 1 gram PO TID × 7 days 1, 5
• Acyclovir: 800 mg PO 5 times daily × 7 days 1

Genital Herpes - Episodic Treatment

Both agents are effective, but valacyclovir offers dosing convenience:

Valacyclovir regimens 1:

• First episode: 1 gram PO BID × 7-10 days
• Recurrent episodes: 500 mg PO BID × 5 days (or 1 gram daily × 5 days)

Acyclovir regimens 1:

• First episode: 400 mg PO TID × 7-10 days (or 200 mg 5×/day)
• Recurrent episodes: 400 mg PO TID × 5 days (or 800 mg BID × 5 days)

Genital Herpes - Suppressive Therapy

Valacyclovir allows once-daily dosing for most patients 1:

• Standard: 500 mg PO daily (or 1 gram daily)
• HIV-infected patients: 500 mg PO BID
• Patients with ≥10 recurrences/year: avoid 500 mg once daily (less effective) 1

Acyclovir suppressive dosing: 400 mg PO BID 1

Herpes Labialis (Cold Sores)

Valacyclovir is the only oral antiviral FDA-approved for cold sores 5, 3:

• 2 grams PO BID × 1 day (two doses 12 hours apart)
• Approved for patients ≥12 years 5

Transmission Reduction

Valacyclovir is the only agent with FDA approval for reducing HSV-2 transmission 1, 5:

• 500 mg daily in source partners reduced symptomatic acquisition by 75% and overall acquisition by 48% 5

When Acyclovir is Preferred or Required

Severe/Disseminated Disease Requiring IV Therapy

IV acyclovir remains the standard for:

• HSV encephalitis: 10 mg/kg IV q8h × 14-21 days 6
• Neonatal HSV (CNS/disseminated): 20 mg/kg IV q8h × 21 days 7
• Severe genital herpes requiring hospitalization: 5-10 mg/kg IV q8h 1

Pediatric Populations

Acyclovir has more extensive pediatric data 7:

• Children <12 years with HSV: acyclovir preferred (limited valacyclovir data)
• Chickenpox (ages 2-18): valacyclovir 20 mg/kg PO TID × 5 days (max 1 gram/dose) is acceptable 5
• Valacyclovir NOT recommended for neonatal HSV suppression (insufficient efficacy data) 5

Moderate-Severe Gingivostomatitis

Start with IV acyclovir (5-10 mg/kg q8h), then transition to oral 7

Cost Considerations

Acyclovir is generally less expensive and may be preferred when cost is prohibitive and dosing frequency is manageable.

Important Caveats

Renal Impairment

Both require dose adjustment; valacyclovir may need more aggressive reduction 5:

• CrCl 30-49: valacyclovir 1 gram q12h (for zoster)
• CrCl 10-29: valacyclovir 1 gram q24h
• CrCl <10: valacyclovir 500 mg q24h

Acyclovir-Resistant HSV

Neither agent is effective; foscarnet is required (40 mg/kg IV q8h or 60 mg/kg IV q12h) 7

Safety Profile

Both agents have comparable safety profiles 1, 2, 8. Adverse events are infrequent and similar in nature between the two drugs.

Clinical Algorithm

For immunocompetent adults/adolescents:

1. Herpes zoster → Valacyclovir 1g TID (superior pain outcomes)
2. Genital herpes (episodic) → Valacyclovir 500mg-1g BID (convenience)
3. Genital herpes (suppression) → Valacyclovir 500mg-1g daily (once-daily option)
4. Cold sores → Valacyclovir 2g BID × 1 day (only approved option)

For severe disease/special populations:

1. CNS involvement, disseminated disease → IV acyclovir
2. Neonates → IV acyclovir
3. Children <12 years → Acyclovir (more data)
4. Significant renal impairment → Consider acyclovir with appropriate dose adjustment

The convenience of valacyclovir's less frequent dosing translates to improved real-world adherence, making it the preferred first-line agent for most outpatient HSV and VZV infections in adults 3, 9.